Cormedix Inc. balance sheet
At the end of fiscal 2025, Cormedix Inc. had total assets of $826m, total liabilities of $421m and shareholders' equity of $405m. It held $145m in cash against $144,626 of debt.
Balance sheet
| Fiscal year | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1 | 2 | 4 | 12 | 8 | 10 | 18 | 16 | 42 | 53 | 43 | 41 | 145 | 257 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — | — | 52 | 171 | 161 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | — | 8 | 30 | 39 |
| Total current assets | 1 | 3 | 5 | 37 | 22 | 13 | 19 | 29 | 48 | 66 | 60 | 115 | 367 | 481 |
| Goodwill | — | — | — | — | — | — | — | — | — | — | — | — | 30 | 30 |
| Total assets | 1 | 3 | 5 | 37 | 22 | 13 | 19 | 29 | 49 | 69 | 62 | 119 | 826 | 904 |
| Accounts payable | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 1 | 1 | 2 | 2 | 2 | 8 | 10 |
| Deferred revenue (current) | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — | — | — | — |
| Total current liabilities | 1 | 2 | 1 | 3 | 4 | 6 | 8 | 6 | 4 | 5 | 6 | 34 | 174 | 187 |
| Long-term debt | — | — | — | — | — | 0 | 6 | — | — | — | — | — | 0 | — |
| Total debt | 0 | 0 | 0 | 0 | 0 | 0 | 6 | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Total liabilities | 1 | 7 | 1 | 3 | 4 | 6 | 14 | 6 | 5 | 6 | 7 | 34 | 421 | 443 |
| Shareholders' equity | −0 | −4 | 4 | 34 | 18 | 7 | 5 | 24 | 44 | 63 | 55 | 85 | 405 | 461 |
| Shares outstanding | — | — | — | — | — | — | 22m | 26m | 34m | 38m | 43m | 64m | 79m | 78m |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Receivables | 17 | 52 | 55 | 43 | 159 | 171 | 155 | 161 |
| Inventory | 7 | 8 | 7 | 10 | 29 | 30 | 31 | 39 |
| Total current assets | 73 | 115 | 145 | 248 | 260 | 367 | 383 | 481 |
| Goodwill | — | — | — | — | 18 | 30 | 30 | 30 |
| Total assets | 78 | 119 | 150 | 253 | 751 | 826 | 816 | 904 |
| Accounts payable | 1 | 2 | 2 | 6 | 20 | 8 | 13 | 10 |
| Total current liabilities | 18 | 34 | 34 | 32 | 134 | 174 | 129 | 187 |
| Long-term debt | — | — | — | — | 150 | 0 | — | — |
| Total debt | — | — | — | — | 150 | 0 | — | — |
| Total liabilities | 19 | 34 | 35 | 32 | 377 | 421 | 379 | 443 |
| Shareholders' equity | 59 | 85 | 115 | 221 | 374 | 405 | 437 | 461 |
| Shares outstanding | 58m | 64m | 68m | 75m | 78m | 79m | 78m | 78m |
Compare with peers
- Arcutis Biotherapeutics, Inc. balance sheet
- Krystal Biotech, Inc. balance sheet
- Ardelyx, Inc. balance sheet
- Adma Biologics, Inc. balance sheet
- Novavax Inc balance sheet
Head to head: ARQT vs CRMDCRMD vs KRYSARDX vs CRMD
More: Biotechnology stocks compared, Health Care sector, rankings of US companies